Breast cancers are clinically classified by the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) gene amplification as ER+/ HER2-, HER2+, and triple-negative (ER-/PR-/HER2-) subtypes. This evidence concerns the gene ESR1 and breast carcinoma.